INMOBI
InMobi, the world’s leading independent marketing cloud, has been recognized by the MMA SMARTIES MENA 2020, receiving 15 awards across a number of categories, acknowledging impactful campaigns with leading consumer brands. The MMA SMARTIES MENA Awards jury consisted of marketing thought leaders from MENA who voted on MMA MENA SMARTIES 2020’s winning campaigns after a thorough evaluation process of more than a hundred submissions.
In addition to the 13 listed below, InMobi won two of the association’s most coveted awards. For the second year running, the mobile industry leader was named Tech Enabler of the Year. And for the first time, it received the SMARTIES MENA 2020 Best-in-Show award for a Mars Snickers campaign it conducted in collaboration with Mediacom UAE and Xaxis UAE.
“2020 was a year unlike anything any of us have ever experienced before, featuring unique challenges that drove us to innovate on new solutions, dig deep into our creative reserves and forge still tighter bonds with our clients,” said Andy Powell, VP and Managing Director, EMEA at InMobi. “It's quite rewarding to see our close collaboration with agency partners, innovative spirit and creativity be acknowledged by the MMA. We thank the judges and salute the inspiring competition from other brands, agencies and technology providers across the region.”
InMobi also received awards in the following 13 categories:
- Location Based Services or Targeting: Hajj Pack Campaign for Hajj Pack / LifeBuoy / Unilever, Magna, Blis, DMS – GOLD
- Innovation: Axe Chill Campaign for Axe / Unilever, Magna, Anghami – GOLD
- Innovation: Snickers Hunger Support Campaign for Snickers / Mars, Mediacom UAE and Xaxis UAE – GOLD
- Machine Learning and AI: Snickers Hunger Support Campaign for Snickers / Mars, Mediacom UAE and Xaxis UAE – GOLD
- Brand Awareness: Vodafone Qatar 5G Launch Campaign – Red Velvet and Stop the Clock for Vodafone Qatar, Wavemaker Qatar – SILVER
- Product/Services Launch: Vodafone Qatar 5G Launch Campaign – Red Velvet and Stop the Clock for Vodafone Qatar, Wavemaker Qatar – SILVER
- COVID-19 Campaign of the Year: stc pay Stay at Home Campaign for stc pay, UM Saudi Arabia – SILVER
- Customer Experience: Snickers Hunger Support Campaign for Snickers / Mars, Mediacom UAE and Xaxis UAE - SILVER
- Data and Insights: Hajj Pack Campaign for Hajj Pack / LifeBuoy / Unilever, Magna, Blis, DMS – SILVER
- Data and Insights: Axe Chill Campaign for Axe / Unilever, Magna, Anghami – BRONZE
- Lead Gen/Direct Responses/Conversions: stc pay Stay at Home Campaign for stc pay, UM Saudi Arabia – BRONZE
- Mobile App: stc pay Stay at Home Campaign for stc pay, UM Saudi Arabia – BRONZE
- mCommerce: stc pay Stay at Home Campaign for stc pay, UM Saudi Arabia – BRONZE
For a full list of MMA SMARTIES MENA 2020 winners, please visit: https://www.mmamena.org/post/mmasmartiesmena2020winners
About InMobi
InMobi drives real connections between brands and consumers by leveraging its technology platforms and exclusive access to mobile intelligence. Its Marketing Cloud creates new paths for brands to understand, identify, engage and acquire connected consumers. As a leading technology company, InMobi has been recognized on both the 2018 and 2019 CNBC Disruptor 50 lists and as one of Fast Company’s 2018 World’s Most Innovative Companies. For more information, visit inmobi.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330006130/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom